Latest News

New data for daclizumab in MS

 

Daclizumab is an IgG1 anti-CD25 monoclonal antibody that blocks IL-2-mediated lymphocyte activation. The drug (Zenapax) was originally used to prevent tissue rejection but was withdrawn by Roche in 2009 due to declining demand.      Read More

TOPICS:

Environmental factors in MS: Air and vitamin D

 

REPORT FROM THE ACTRIMS-ECTRIMS – BOSTON, MA, SEPTEMBER 10-13, 2014 – Few studies have examined the potential impact of ambient air quality and airborne particulates on multiple sclerosis. A decade ago, a study in Finland suggested that the frequency of MS relapses was higher with increasing levels of inhaled particulates (Oikonen et al. Neuroepidemiology 2003;22:95-99). Read More

TOPICS: